AR128382A1 - Radiofármacos dirigidos a ntsr1 y terapia de combinación de inhibidor de respuesta de daños de dna - Google Patents

Radiofármacos dirigidos a ntsr1 y terapia de combinación de inhibidor de respuesta de daños de dna

Info

Publication number
AR128382A1
AR128382A1 ARP230100211A ARP230100211A AR128382A1 AR 128382 A1 AR128382 A1 AR 128382A1 AR P230100211 A ARP230100211 A AR P230100211A AR P230100211 A ARP230100211 A AR P230100211A AR 128382 A1 AR128382 A1 AR 128382A1
Authority
AR
Argentina
Prior art keywords
mammal
group
radiopharmaceutical
dna damage
administering
Prior art date
Application number
ARP230100211A
Other languages
English (en)
Spanish (es)
Inventor
John R Forbes
Saleemulla Mahammad
Original Assignee
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc filed Critical Fusion Pharmaceuticals Inc
Publication of AR128382A1 publication Critical patent/AR128382A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ARP230100211A 2022-01-28 2023-01-30 Radiofármacos dirigidos a ntsr1 y terapia de combinación de inhibidor de respuesta de daños de dna AR128382A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263304178P 2022-01-28 2022-01-28

Publications (1)

Publication Number Publication Date
AR128382A1 true AR128382A1 (es) 2024-04-24

Family

ID=87469883

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100211A AR128382A1 (es) 2022-01-28 2023-01-30 Radiofármacos dirigidos a ntsr1 y terapia de combinación de inhibidor de respuesta de daños de dna

Country Status (12)

Country Link
US (1) US20250177581A1 (cg-RX-API-DMAC10.html)
EP (1) EP4469092A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025503215A (cg-RX-API-DMAC10.html)
KR (1) KR20240142499A (cg-RX-API-DMAC10.html)
CN (1) CN119136846A (cg-RX-API-DMAC10.html)
AR (1) AR128382A1 (cg-RX-API-DMAC10.html)
AU (1) AU2023211719A1 (cg-RX-API-DMAC10.html)
CA (1) CA3249955A1 (cg-RX-API-DMAC10.html)
IL (1) IL314530A (cg-RX-API-DMAC10.html)
MX (1) MX2024009312A (cg-RX-API-DMAC10.html)
TW (1) TW202337451A (cg-RX-API-DMAC10.html)
WO (1) WO2023141717A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4355325A4 (en) * 2021-06-16 2025-05-07 Fusion Pharmaceuticals Inc. COMBINATION OF A NEUROTENSIN RECEPTOR-BINDING COMPOUND AND FOLFIRINOX

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2478695B1 (es) * 2012-12-20 2015-04-28 Servicio Andaluz De Salud Dispositivo para inducir hipotermia terapéutica
KR20210099073A (ko) * 2018-12-03 2021-08-11 퓨전 파마슈티칼즈 인크. 방사성면역접합체와 체크포인트 억제제의 조합 요법

Also Published As

Publication number Publication date
EP4469092A1 (en) 2024-12-04
JP2025503215A (ja) 2025-01-30
TW202337451A (zh) 2023-10-01
MX2024009312A (es) 2024-08-06
US20250177581A1 (en) 2025-06-05
CA3249955A1 (en) 2023-08-03
AU2023211719A1 (en) 2024-08-15
KR20240142499A (ko) 2024-09-30
WO2023141717A1 (en) 2023-08-03
CN119136846A (zh) 2024-12-13
IL314530A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
Wardman Chemical radiosensitizers for use in radiotherapy
JP7217752B2 (ja) Acss2阻害剤およびその使用方法
ES2165830T1 (es) Kit para radiomarcar proteinas con itrio-90.
AR119424A1 (es) Derivados de 3-oxo-4h-quinoxalina y oxo-1h-naftiridina como inhibidores de parp
BR0210971A (pt) Formas inovadoras de dosagem de benzimidazol substituìdo e método para usar as mesmas
DOP2002000333A (es) Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
HRP20240952T1 (hr) Spojevi koji ciljaju psma i njihova uporaba
EP4545143A3 (en) Early intervention methods to prevent or ameliorate toxicity
US20100022514A1 (en) Heterocycle Compounds and Methods of Use Thereof
SK286676B6 (sk) Použitie ftalazínových derivátov
AR067850A1 (es) Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa y kit
MX9303441A (es) Procedimiento para la preparacion de acido clavulanico.
AR063869A1 (es) Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante
Boughton et al. Alarin stimulates food intake and gonadotrophin release in male rats
Fukuda et al. Kinetics of porphyrin accumulation in cultured epithelial cells exposed to ALA.
US20130012709A1 (en) NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
BR112017012841A2 (pt) complexos radiofarmacêuticos
AR128381A1 (es) Radiofármacos dirigidos a ntsr1 y terapia de combinación de inhibidores punto de control
BRPI0713013A2 (pt) compostos orgánicos
AR128385A1 (es) Radiofármacos dirigidos al psma e inhibidor de punto de control
WO2024078568A1 (zh) Akr1c3激活抗癌前药化合物与镇痛药物联用治疗伴有疼痛的癌症患者
DK360584A (da) Triazol-pyrimidinderivater og fremgangsmaade til fremstilling deraf samt disses terapeutiske anvendelse som cardiotoniske midler
MX2024009312A (es) Radiofarmacos dirigidos a ntsr1 y terapia de combinacion de inhibidor de respuesta de da?os de dna.
AR132418A1 (es) Agentes radiofarmacéuticos dirigidos a psma y terapia de combinación con inhibidores de la respuesta al daño de adn
WO2018039581A1 (en) Use of hdac6 inhibitors for preventing and treating renal cystogenesis, renal cell carcinoma, and renal ciliopathies